Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker MC
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Kenneth Shropshire Director | MC Moelis & Company | Sale | 1,881 | $69.06 | $129.9K Sale | Form 4 ↗ |
| Aug 4, 2026 | Osamu R. Watanabe General Counsel, Secretary | MC Moelis & Company | Sale | 4,850 | $69.30 | $336.1K Sale | Form 4 ↗ |
| Feb 19, 2026 | Osamu R. Watanabe General Counsel, Secretary | MC Moelis & Company | Sale | 2,765 | $62.23 | $172.1K Sale | Form 4 ↗ |
| Aug 22, 2025 | Kenneth Shropshire Director | MC Moelis & Company | Sale | 2,615 | $72.52 | $189.6K Sale | Form 4 ↗ |
| Jul 25, 2025 | Osamu R. Watanabe General Counsel, Secretary | MC Moelis & Company | Sale | 6,340 | $72.64 | $460.5K Sale | Form 4 ↗ |
| Feb 21, 2025 | Kenneth Shropshire Director | MC Moelis & Company | Sale | 2,551 | $72.30 | $184.4K Sale | Form 4 ↗ |
| Feb 19, 2025 | Ciafone Katherine Pilcher Chief Operating Officer | MC Moelis & Company | Sale | 3,515 | $74.00 | $260.1K Sale | Form 4 ↗ |
| Feb 19, 2025 | Eric Cantor Vice Chairman, MD, Director | MC Moelis & Company | Sale | 16,530 | $74.00 | $1.2M Sale | Form 4 ↗ |
| Feb 19, 2025 | Joseph Simon Chief Financial Officer | MC Moelis & Company | Sale | 5,758 | $74.00 | $426.1K Sale | Form 4 ↗ |
| Feb 19, 2025 | Kenneth Moelis Chairman, CEO, Director | MC Moelis & Company | Sale | 9,712 | $74.00 | $718.7K Sale | Form 4 ↗ |
| Feb 19, 2025 | Christopher Callesano Principal Accounting Officer | MC Moelis & Company | Sale | 1,282 | $74.00 | $94.9K Sale | Form 4 ↗ |
| Feb 19, 2025 | Jeffrey Raich Co-President, MD | MC Moelis & Company | Sale | 8,722 | $74.00 | $645.4K Sale | Form 4 ↗ |
| Feb 19, 2025 | Osamu R. Watanabe General Counsel, Secretary | MC Moelis & Company | Sale | 5,661 | $74.00 | $418.9K Sale | Form 4 ↗ |
| Feb 19, 2025 | Navid Mahmoodzadegan Co-President, MD | MC Moelis & Company | Sale | 9,406 | $74.00 | $696.0K Sale | Form 4 ↗ |
| Nov 7, 2024 | Christopher Callesano Principal Accounting Officer | MC Moelis & Company | Sale | 885 | $80.00 | $70.8K Sale | Form 4 ↗ |
15 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances